Climb Bio Inc. (NASDAQ: CLYM) presented initial Phase 1 safety data and translational modeling results for CLYM116, its anti-APRIL monoclonal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE